Dr Stephen Elliman of Orbsen Therapeutics, Professor Frank Barry of NUI Galway, Alison Campbell of KTI and Minister Damien English.
Mar 31 2015 Posted: 16:50 IST

NUI Galway spin-out Orbsen Therapeutics has been recognised by the annual Knowledge Transfer Ireland Impact Awards (KTI). Orbsen Therapeutics, a biotech company, was nominated for the Spin-out Company Impact Award. The KTI Awards acknowledge cases where knowledge transfer activities had a particularly significant impact on wider society and the economy.

The announcement was made last week at a ceremony in the Hilton Hotel, Dublin. Minister of State for Skills, Research and Innovation, Damien English T.D. presented the awards, giving credit not only to the companies, but also to the research performing organisations that supported the success.

Orbsen Therapeutics is Ireland’s leading cell therapy bio-technology company, based on the NUI Galway campus. It was founded by Professor Frank Barry and Professor Tim O’Brien of the Regenerative Medicine Institute (REMEDI) at the University. Orbsen has rapidly developed and patented a method for purifying a novel stromal cell from several adult human tissues. Stromal cells are rare cells (less than 0.01%) found in many tissues where they regulate and limit the immune system from launching attacks that can damage tissues during disease. Orbsen’s discovered and patented a method for specifically purifying these rare, therapeutic stromal cells and developing them for clinical use.

To accelerate the clinical development of their cell therapy (Cyndacel-M), Orbsen has collaborated with 24 independent research laboratories across the EU to secure €24 million in EU research funding between 2013 and 2015. These EU funds are being used to develop Cyndacel-M through early-stage clinical safety trials across the EU. Specifically, between 2015 and 2018, Cyndacel-M will be tested in clinical safety trials in patients suffering from Diabetic Foot Ulcers, Autoimmune Liver Disease, Corneal Transplant Rejection, Diabetic Kidney Disease and Acute Respiratory Distress Syndrome. In additon, the EU funds have enabled Orbsen to grow from a group of founders to a diverse team of 14 research scientists in the last two years.

NUI Galway has supported Orbsen Therapeutics from the start, assisting in the development of Orbsen’s technology, while providing expertise and facilities. The University’s Technology Transfer Office then helped Orbsen develop a rapid Intelectual Property protection strategy, allowing Orbsen Therapeutics to begin the clinical trial process. NUI Galway has also been instrumental in connecting Orbsen with a network of EU collaborators to further their research.

Orbsen Chief Scientific Officer Dr Stephen Elliman says of the nomination and the relationship with NUI Galway: “We are honoured to be nominated for KTI Spin-out Company of the Year. It recognises the huge efforts made by our own research team and our network of research partners to move Cyndacel to the clinic so efficiently. Also, we are grateful to NUI Galway for their support over the years. The TTO have been instrumental in our progress to this point and we continue to enjoy working with them.”

Fiona Neary, Business Development Manager at Ignite Technology Transfer Office NUI Galway adds “We are delighted that Orbsen have been recognised in this category. The team has worked incredibly hard to achieve their goals and continue to go from strength to strength. They have always been a joy to work with.”

For more information: http://orbsentherapeutics.com/ http://tto.nuigalway.ie/en/

-ends-

 

Marketing and Communications Office

PreviousNext

Featured Stories